Breakthrough in the Treatment of One of the Most Resistant Types of Cancer 0 24

Scientists from Okayama and Tohoku Universities have proposed a new approach to treating pancreatic cancer—a tumor known for its almost impermeable protective environment. In a study published in the journal Small, it is shown that blocking the collagen signaling pathway significantly improves the penetration of anticancer drugs into the tumor tissue.

The key role is played by the DDR1 receptor, which is activated by collagen. Previously, collagen was mainly viewed as a 'physical barrier' preventing drugs from reaching cancer cells. However, it turns out that it also triggers a signaling cascade that enhances fibrosis and further tightens the tumor environment. Suppressing DDR1 breaks this vicious cycle, reduces fibrosis, and makes the tumor more permeable to macromolecular drugs—including antibodies and nanomedicines.

Additionally, the researchers discovered a concerning effect of some experimental therapies. MEK inhibitors, which were tested for pancreatic cancer, unexpectedly increased collagen production, thereby worsening drug delivery. This effect could be neutralized by simultaneously blocking DDR1—a possible explanation for why several clinical trials with MEK inhibitors have been unsuccessful.

The authors emphasize that this work changes the understanding of the role of fibrosis in oncology and opens the way to new combination treatment strategies. In the future, this approach could enhance the effectiveness of therapy not only for pancreatic cancer but also for other diseases where dense connective tissue hinders drug action.